Oncimmune Holdings PLC articles
Overcoming issues of heterogeneity in disease classification and enabling new approaches to successful drug development.
SLE is an autoimmune disease with a wide range of clinical manifestations. It affects approximately 5 million people worldwide and its prevalence varies in different geographies. SLE accounts for around 70% of all cases of lupus, other forms being cutaneous lupus, drug-induced lupus and neonatal lupus. In around 50% of people living with SLE, a major o
Adam talks to Dr Parag Mallick from Stanford University where he is a Professor. Having originally trained as an engineer biochemist, Parag`s research is diverse and spans computational and experimental systems biology, cancer biology, and nanotechnology.
Parag talks about the diverse applications of proteomics and the value of bringing together different perspectives and disciplines to tackle challenging problems like biomarker analysis and personalised medicine. He also talks about
How autoantibody profiling can further unlock the success of CPI therapy
Immunotherapy has revolutionised the treatment of cancers, improving the prognosis for a variety of malignancies. One of the key elements in the immunotherapy war chest are checkpoint inhibitors (CPIs) which have been the main drivers behind this progress. These pioneering drugs, however, are not perfect, with a significant proportion of patients not responding. They also have the p
An unmet need for disease-modifying therapy persists for patients with Systemic Sclerosis
SSc is an autoimmune disease characterised by widespread vascular injury, progressive fibrosis of the skin and internal organs, and a specific pattern of autoantibodies. The clinical manifestations of SSc are highly heterogenous with significant internal organ manifestations causing a greater mortality rate than any other rheumatic disease. The diverse clinical spectrum and course o
Annalisa Jenkins` inspirational career spans over 25 years in the global biopharma industry – she started her career at St Barts, in London, where she trained as a cardiologist, before joining the British Royal Navy as a medical officer during the Gulf Conflict, achieving the rank of surgeon lieutenant commander during her time there.
Annalisa spent almost two decades producing a pipeline of innovation at Bristol Myers Squibb and Merck Serono – she has built and led scient